News Update - Alliqua, Inc. (OTCQB: ALQAd) - December
Alliqua Appoints Perry A. Karsen to Board of Directors
CEO of Celgene Cellular Therapeutics To Add Further Depth
and Value to Alliqua’s Board - Increases Size of Board to Nine Members
LANGHORNE, PA – December 4, 2013 -- Alliqua, Inc. (OTCQB:ALQAD)
(“Alliqua” or the “Company”) has appointed Perry A. Karsen to its Board of
Directors, increasing the size of the Board to nine members.
Mr. Karsen, age 58, is Chief Executive Officer of Celgene Cellular Therapeutics,
a wholly owned subsidiary of Celgene Corporation, for which Mr. Karsen also
serves as Executive Vice President and Chief Operations Officer.
Mr. Karsen said, “Last month, I was pleased to help oversee the licensing of
advanced wound care products, Biovance® and Extracellular Matrix (ECM), from
Celgene Cellular Therapeutics to Alliqua. I am impressed by Alliqua’s existing
suite of wound care products and I look forward to working with Alliqua’s
management as Alliqua expands its sales, marketing and distribution
David Johnson, Chief Executive Officer of Alliqua, said, “As part of our
transaction with Celgene that was publicly announced on November 19, Celgene
received a right to appoint a director to our Board of Directors. I am delighted
that Perry Karsen has agreed to assume this role. He possesses a profound
knowledge of the wound care space, and has demonstrated a deep commitment to its
further development. We are privileged to have him help us as we continue to
pursue our corporate goals.”
About Alliqua, Inc.
Alliqua, Inc. (ALQAD) ("Alliqua") is a biopharmaceutical company focused on the
development, manufacturing, and distribution of proprietary transdermal wound
care and drug delivery technologies. Alliqua's technology platform produces
hydrogels, a 3-dimensional cross-linked network of water soluble polymers
capable of numerous chemical configurations.
Alliqua currently markets its line of 510(k) FDA-approved hydrogel products for
wound care under the SilverSeal® brand, as well as the sorbion sachet S and
sorbion sana wound care products. Alliqua's electron beam production process,
located at its 16,000 square foot GMP manufacturing facility in Langhorne, PA,
allows Alliqua to develop and custom manufacture a wide variety of hydrogels.
Alliqua's hydrogels can be customized for various transdermal applications to
address market opportunities in the treatment of wounds as well as the delivery
of numerous drugs or other agents for pharmaceutical and cosmetic industries.
Additionally, Alliqua's drug delivery platform, in combination with certain
active pharmaceutical ingredients, can provide pharmaceutical companies with a
transdermal technology to enhance patient compliance and potentially extend the
patent life of valuable drug franchises.
For additional information, please visit http://www.alliqua.com. To receive
future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts.
Any statements contained in this press release regarding our ongoing research
and development and the results attained by us to-date have not been evaluated
by the Food and Drug Administration.
Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements are
generally identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend," or "project"
or the negative of these words or other variations on these words or comparable
terminology. The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to numerous factors
and uncertainties outside of our control that can make such statements untrue,
including, but not limited to, inadequate capital, adverse economic conditions,
intense competition, lack of meaningful research results, entry of new
competitors and products, adverse federal, state and local government
regulation, termination of contracts or agreements, technological obsolescence
of our products, technical problems with our research and products, price
increases for supplies and components, inability to carry out research,
development and commercialization plans, loss or retirement of key executives
and research scientists and other specific risks. We currently have no
commercial products intended to diagnose, treat, prevent or cure any disease.
The statements contained in this press release regarding our ongoing research
and development and the results attained by us to-date have not been evaluated
by the Food and Drug Administration. There can be no assurance that further
research and development, and/or whether clinical trial results, if any, will
validate and support the results of our preliminary research and studies.
Further, there can be no assurance that the necessary regulatory approvals will
be obtained or that we will be able to develop new products on the basis of our
technologies. In addition, other factors that could cause actual results to
differ materially are discussed in our Annual Report on Form 10-K/A filed with
the SEC on May 16, 2013, and our most recent Form 10-Q filings with the SEC.
Investors and security holders are urged to read these documents free of charge
on the SEC's web site at http://www.sec.gov. We undertake no obligation to
publicly update or revise our forward-looking statements as a result of new
information, future events or otherwise.
Brian M. Posner, +1-215-702-8550
Chief Financial Officer
Dian Griesel Int'l.
Cheryl Schneider, +1-212-825-3210
Dian Griesel Int'l.
Susan Forman or Laura Radocaj, +1-212-825-3210
SOURCE: Alliqua, Inc.
FN Media Group LLC (FNMG) owns and operates
FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates
electronic information through multiple online media channels. FNMG's intended
purposes are to deliver market updates and news alerts issued from private and
publicly trading companies as well as providing coverage and increased awareness
for companies that issue press to the public via online newswires. FNMG and its
affiliated companies are a news dissemination and financial marketing solutions
provider and are NOT a registered broker/dealer/analyst/adviser, holds no
investment licenses and may NOT sell, offer to sell or offer to buy any
security. FNMG's market updates, news alerts and corporate profiles are NOT a
solicitation or recommendation to buy, sell or hold securities. The material in
this release is intended to be strictly informational and is NEVER to be
construed or interpreted as research material. All readers are strongly urged to
perform research and due diligence on their own and consult a licensed financial
professional before considering any level of investing in stocks. The companies
that are discussed in this release may or may not have approved the statements
made in this release. Information in this release is derived from a variety of
sources that may or may not include the referenced company's publicly
disseminated information. The accuracy or completeness of the information is not
warranted and is only as reliable as the sources from which it was obtained.
While this information is believed to be reliable, such reliability cannot be
guaranteed. FNMG disclaims any and all liability as to the completeness or
accuracy of the information contained and any omissions of material fact in this
release. This release may contain technical inaccuracies or typographical
errors. It is strongly recommended that any purchase or sale decision be
discussed with a financial adviser, or a broker-dealer, or a member of any
financial regulatory bodies. Investment in the securities of the companies
discussed in this release is highly speculative and carries a high degree of
risk. FNMG is not liable for any investment decisions by its readers or
subscribers. Investors are cautioned that they may lose all or a portion of
their investment when investing in stocks. This release is not without bias, and
is considered a conflict of interest if compensation has been received by FNMG
for its dissemination. To comply with Section 17(b) of the Securities Act of
1933, FNMG shall always disclose any compensation it has received, or expects to
receive in the future, for the dissemination of the information found herein on
behalf of one or more of the companies mentioned in this release. For current
services performed FNMG has been compensated one thousand two hundred fifty
dollars for Alliqua, Inc.
news coverage by the Company. FNMG HOLDS NO SHARES OF
This release contains "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E the Securities
Exchange Act of 1934, as amended and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words such as "may",
"future", "plan" or "planned", "will" or "should", "expected," "anticipates",
"draft", "eventually" or "projected". You are cautioned that such statements are
subject to a multitude of risks and uncertainties that could cause future
circumstances, events, or results to differ materially from those projected in
the forward-looking statements, including the risks that actual results may
differ materially from those projected in the forward-looking statements as a
result of various factors, and other risks identified in a company's annual
report on Form 10-K or 10-KSB and other filings made by such company with the
Securities and Exchange Commission. You should consider these factors in
evaluating the forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this release are
made as of the date hereof and FNMG undertakes no obligation to update such